UnitedHealthcare · Tirzepatide · US health-plan appeal rights

Tirzepatide denied as non-formulary by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Non-formulary doesn't mean uncoverable. Most plans have a formulary-exception process: the appeal needs to show the formulary alternatives are inappropriate for your specific clinical situation.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-05-04

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

Zepbound (obesity): BMI >=30 or >=27 with comorbidity. Mounjaro (T2DM): HbA1c >=7% despite metformin trial.

Source policy: Tirzepatide (Zepbound, Mounjaro) Prior Authorization

What works in the appeal

Step therapy: Document contraindications to required agents (phentermine: uncontrolled hypertension, cardiovascular disease, hyperthyroidism; topiramate: pregnancy risk, kidney stones, glaucoma; Contrave: uncontrolled hypertension, seizure disorder, eating disorders, opioid use). If prior trials exist, submit records showing 12+ week trial with inadequate response (<5% weight loss) or intolerable side effects. Clinical necessity: Cite FDA approval of Zepbound (tirzepatide) for chronic weight management in adults with BMI ≥30 or ≥27 with weight-related comorbidity (May 2023). Reference SURMOUNT-1 trial showing 15-21% weight loss vs 3% placebo. For patients with prediabetes or metabolic syndrome, emphasize cardiometabolic benefit and diabetes prevention (58% reduction in progression per DPP trial). Request expedited appeal if patient has failed/cannot tolerate step therapy agents due to medical contraindications.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other denial reasons for UnitedHealthcare Tirzepatide

denied as not medically necessary denied for failing step therapy denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.